Development of a M cell-targeted microparticulate platform, BSK02™, for oral immunization against the ovarian cancer antigen, sperm protein 17.
Development of a M cell-targeted microparticulate platform, BSK02™, for oral immunization against the ovarian cancer antigen, sperm protein 17.
复制标题
DOI：
10.1002/jbm.b.34092
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
J. Mattila;L. Mirandola;M. Chiriva-Internati
中科院分区：
文献类型：
--
作者：
J. Mattila;L. Mirandola;M. Chiriva-Internati
虽然卵巢癌仅占所有女性癌症病例的约5%，但它是妇女癌症死亡的第五大原因。我们已经评估了一种口服微颗粒疫苗的潜力，该疫苗含有一种免疫优势表位肽，该表位肽来源于癌/睾丸抗原精子蛋白17 (SP17)，在卵巢癌中异常表达，以延缓疾病的进展。将肽抗原和免疫刺激toll样受体9配体CpG寡核苷酸结合到喷雾干燥的微颗粒中，该微颗粒由肠溶和缓释聚合物组成，并与针对肠道相关淋巴组织中存在的微折叠细胞的金蕨凝集素一起。将这些颗粒口服给药于一周前用表达sp17的ID8 OC细胞攻毒的小鼠。对接种小鼠脾细胞的分析显示，在SP17抗原的再刺激下，IFN-γ+/CD8+淋巴细胞被强烈激活。此外，与安慰剂治疗的动物相比，接种疫苗的动物在肿瘤攻击后四周表现出腹水/肿瘤体积的显著延迟（p = 0.005）。综上所述，我们的研究结果表明，口服SP17微颗粒疫苗可以作为一线治疗后残留肿瘤或复发概率高的卵巢癌患者的有效巩固策略。©2018 Wiley期刊公司[J]中国生物医学工程学报，2016,31(2):559 - 559。
Although it only accounts for approximately 5% of all female cancer cases, ovarian cancer (OC) ranks as the fifth leading cause of death due to cancer in women. We have evaluated the potential of an orally administered microparticulate vaccine incorporating an immunodominant epitope peptide derived from the cancer/testis antigen sperm protein 17 (SP17) aberrantly expressed in OC, to retard the progression of the disease. The peptide antigen and the immune-stimulatory toll-like receptor 9 ligand CpG oligonucleotide were incorporated into spray dried microparticles composed of enteric and sustained release polymers together with the Aleuria aurantia lectin targeting microfold cells present in the gut-associated lymphoid tissue. These particles were administered via oral route to mice challenged week prior with SP17-expressing ID8 OC cells. Analysis of splenocytes harvested from vaccinated mice revealed strong activation of IFN-γ+/CD8+ lymphocytes in response to re-stimulation with the SP17 antigen. Moreover, vaccinated animals showed significant retardation of ascites/tumor volume in comparison to placebo-treated animals four weeks after the tumor challenge (p = 0.005). Taken together, our results suggest that vaccination against SP17 using orally administered microparticles could potentially be used as an effective consolidation strategy for OC patients with residual tumor or high probability for relapse following first-line treatments. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 107B: 29-36, 2019.